Impact of clinical symptoms and diagnosis: the electronic Person-Specific Outcome Measure (ePSOM) development programme

INTRODUCTION: Regulatory bodies recommend that outcome measures used in Alzheimer’s disease (AD) clinical trials capture clinically meaningful changes for the trial participant. However, commonly used outcome measures do not reflect the individual’s views on what matters to them individually. The ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Saunders, S., Sheehan, S., Muniz-Terrera, G., Luz, S., Ritchie, C. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982721/
https://www.ncbi.nlm.nih.gov/pubmed/35380317
http://dx.doi.org/10.1186/s41687-022-00433-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982721/
https://www.ncbi.nlm.nih.gov/pubmed/35380317
http://dx.doi.org/10.1186/s41687-022-00433-2

Ejemplares similares